Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Tandem Diabetes Care revenue
Tandem Diabetes Care's revenue is $940.2 million.
What is Tandem Diabetes Care's revenue?
- Tandem Diabetes Care's revenue growth from 2013 to 2024 is 3,141.3%.
- Tandem Diabetes Care has 1,500 employees, and the revenue per employee ratio is $626,802.
- Tandem Diabetes Care's peak quarterly revenue was $282.6M in 2024(q4).
- Tandem Diabetes Care peak revenue was $940.2M in 2024.
- Tandem Diabetes Care annual revenue for 2023 was 747.7M, -6.68% growth from 2022.
- Tandem Diabetes Care annual revenue for 2024 was 940.2M, 25.74% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Tandem Diabetes Care historical revenue
Tandem Diabetes Care's peak revenue was $940.2M in 2024. The peak quarterly revenue was $282.6M in 2024(q4).
Tandem Diabetes Care's revenue increased from $29.0m in 2013 to $940.2M currently. That's a 3,141.3% change in annual revenue.
Tandem Diabetes Care annual revenue
Tandem Diabetes Care annual revenue over time
| Fiscal year / year | Tandem Diabetes Care revenue |
|---|---|
| 2013 | $29.0M |
| 2014 | $49.7M |
| 2015 | $72.9M |
| 2016 | $84.2M |
| 2017 | $107.6M |
| 2018 | $183.9M |
| 2019 | $362.3M |
| 2020 | $498.8M |
| 2021 | $702.8M |
| 2022 | $801.2M |
| 2023 | $747.7M |
| 2024 | $940.2M |
Rate Tandem Diabetes Care's financial transparency
Tandem Diabetes Care annual growth
Tandem Diabetes Care saw the greatest revenue growth in 2019, when revenue increased by 97.05%.
Tandem Diabetes Care had the lowest revenue growth in 2022, when revenue changed by 14.0%.
Tandem Diabetes Care annual growth rate over time
| Year | Tandem Diabetes Care growth |
|---|---|
| 2014 | 71%↑ |
| 2015 | 47%↑ |
| 2016 | 16%↑ |
| 2017 | 28%↑ |
| 2018 | 71%↑ |
| 2019 | 97%↑ |
| 2020 | 38%↑ |
| 2021 | 41%↑ |
| 2022 | 14%↑ |
| 2023 | -7%↓ |
| 2024 | 26%↑ |
Tandem Diabetes Care quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Tandem Diabetes Care quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | - | - | $10.2M |
| 2014 | $8.1M | $10.3M | $13.5M | $17.9M |
| 2015 | $12.3M | $15.7M | $15.7M | $29.1M |
| 2016 | $20.1M | $23.0M | $12.3M | $28.9M |
| 2017 | $19.0M | $21.3M | $27.0M | $40.3M |
| 2018 | $27.3M | $34.1M | $46.3M | $76.2M |
| 2019 | $66.0M | $93.3M | $94.7M | $108.4M |
| 2020 | $97.9M | $109.2M | $123.6M | $168.1M |
| 2021 | $141.0M | $172.1M | $179.6M | $210.0M |
| 2022 | $175.9M | $200.3M | $204.5M | $220.5M |
| 2023 | $169.4M | $195.9M | $185.6M | $196.8M |
| 2024 | $191.7M | $221.9M | $244.0M | $282.6M |
Tandem Diabetes Care jobs nearby
Do you work at Tandem Diabetes Care?
Did Tandem Diabetes Care meet its revenue projections?
Tandem Diabetes Care financial information
| CEO | John F. Sheridan |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 1,500 |
| Date Founded | 2006 |
| Headquarters | San Diego, California |
| Number of Locations | 1 |
| Revenue | $940.2M |
| Net Income | -$94,594,000 |
| Gross Proft | $489.6M (2024) |
| PE Ratio | -25.39 |
| Tax Rate | -0.0% |
| Market Capitalization | $2.4B |
| Total Assets | $1,052,785,000 |
| Ticker | TNDM |
Tandem Diabetes Care jobs you might like
Tandem Diabetes Care financing
Tandem Diabetes Care received early financing of $13.0M on 2008-07-07.
| Series | Round size | Date |
|---|---|---|
| Series B | $13M | 07/2008 |
| Series C | $53M | 01/2010 |
| Debt Financing | $12M | 08/2011 |
| Series D | $36.4M | 09/2012 |
| Debt Financing | $80M | 01/2013 |
| Post Ipo Equity | $23.1M | 03/2017 |
| Post Ipo Equity | $69M | 02/2018 |
| Post Ipo Equity | $115M | 08/2018 |
Tandem Diabetes Care investors
| Investors | Security type |
|---|---|
| Second Technology Capital Investors | Series B |
| TPG Biotech | Series B |
| Domain Associates | Series B |
| Delphi Ventures | Series C |
| HLM Venture Partners | Series C |
| TPG Biotech | Series C |
| Domain Associates | Series C |
| Delphi Ventures | Series D |
| JOHN LIVINGSTON | Series D |
| HLM Venture Partners | Series D |
| TPG Biotech | Series D |
| Domain Associates | Series D |
| CRG LP | Debt Financing |
Tandem Diabetes Care competitors
Tandem Diabetes Care's top competitor, McKesson, earned an annual revenue of $309.0B.
Tandem Diabetes Care's smallest competitor is iCAD with revenue of $33.6M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Stryker | $69,470 | $22.6B | 43,000 | 1,690 |
| Intersect ENT | $67,446 | $106.7M | 393 | - |
| NuVasive | $75,654 | $1.2B | 2,800 | 22 |
| Danaher | $65,463 | $23.9B | 80,000 | 1,604 |
| Varian Medical Systems | $104,569 | $3.2B | 10,000 | 11 |
| iCAD | $88,605 | $33.6M | 137 | 2 |
| Invuity | $63,343 | $39.6M | 161 | - |
| Dexcom | $78,550 | $4.0B | 3,900 | 180 |
| Ldr | $61,132 | $164.5M | 562 | 1 |
| CoolSculpting | $73,648 | $342.1M | 686 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Tandem Diabetes Care highest paying jobs
Zippia gives an in-depth look into the details of Tandem Diabetes Care, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Tandem Diabetes Care. The employee data is based on information from people who have self-reported their past or current employments at Tandem Diabetes Care. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Tandem Diabetes Care. The data presented on this page does not represent the view of Tandem Diabetes Care and its employees or that of Zippia.
Tandem Diabetes Care may also be known as or be related to TANDEM DIABETES CARE INC, Tandem Diabetes Care, Tandem Diabetes Care Inc, Tandem Diabetes Care Inc. and Tandem Diabetes Care, Inc.